How to come off Wegovy safely: what actually happens when you stop

What happens to your body when you stop taking Wegovy?

Semaglutide's half-life is roughly five weeks, so it clears the body slowly after the last dose. During that window you may notice hunger returning before the medicine has fully gone. Research from the STEP 1 extension study found that participants who stopped semaglutide after 68 weeks regained most of the weight they had lost within the following year, around two-thirds of it by week 120. That is not a failure of willpower. The medicine was actively suppressing appetite signals; once it is no longer there, those signals reassert themselves.

Practically, this means the weeks after stopping are a period of heightened risk for old eating patterns to creep back. People often describe it as a gradual return of background hunger that they had forgotten was normal for them. Knowing it is coming makes it easier to prepare for. Understanding how long Wegovy takes to work can help frame the reverse: the same receptor system that took weeks to reach its full effect takes weeks to unwind it.

Some people also notice their digestion changes again in the weeks after stopping, since gastric emptying returns to its pre-treatment rate. For most this settles without any intervention, but if gastrointestinal symptoms worsen rather than ease, particularly severe stomach pain, tell your GP or prescriber. The NHS semaglutide patient information page lists the signs that warrant prompt medical attention.

Is there a recommended way to taper rather than stop all at once?

The Wegovy SmPC does not specify a mandatory dose-reduction schedule before stopping, unlike some other medicines. In practice, though, many UK prescribers prefer to step the dose down across two or three months rather than moving straight to zero from a high maintenance dose. The reasoning is straightforward: a gradual reduction gives the body more time to adjust, often reduces the intensity of returning hunger, and allows you and your prescriber to monitor your weight and how you are managing at each step.

Whether a taper is appropriate in your case depends on several things: how long you have been on treatment, which dose you are on, whether you are stopping by choice or because of a side effect, and what support structures you have around lifestyle change. This is exactly the kind of conversation to have before your final pen rather than after it. A prescriber who knows your full history can weigh those factors in a way a general guide cannot.

If you are considering stopping because of cost, it is worth knowing what the full private prescription includes before making that call. Wegovy pricing varies considerably between providers, and what appears to be a saving from one source may not include the clinical review and aftercare that genuinely support a safe transition.

How do you reduce the risk of regaining weight after stopping?

The evidence is clear that the benefits of semaglutide are sustained largely for as long as the medicine is taken. That is not unusual for a chronic condition treatment. The practical implication is that stopping successfully (without significant regain) tends to require deliberate preparation, not just stopping the injections.

A few things make a meaningful difference. Protein intake matters more during the withdrawal period, since satiety signals from the medicine are fading and protein is one of the most reliable dietary tools for managing hunger independently. Resistance and strength activity helps preserve the lean mass that tends to drop alongside fat during active treatment. And keeping a consistent eating pattern (regular meals, avoiding highly processed foods that bypass fullness signals) reduces the likelihood of a rapid return to pre-treatment habits.

None of that is a simple fix. Managing weight after Wegovy is a topic with its own depth, but the short version is that the lifestyle framework the medicine was supposed to sit alongside needs to be firmly in place before the last dose, not assembled afterwards. Your prescriber or a dietitian can help you build that plan in the weeks running up to stopping.

When should you speak to a clinician rather than stopping on your own?

Most people can discuss stopping with their prescriber at a routine review. But a few situations make it more urgent to get clinical input first. If you are stopping because of an adverse effect (particularly persistent nausea, vomiting that is making it difficult to stay hydrated, or abdominal pain) your prescriber needs to know straight away. Some of those symptoms warrant further investigation before you simply discontinue. The MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as a rare but serious risk with GLP-1 medicines; severe stomach pain that spreads to the back, with or without vomiting, needs same-day medical assessment, not a note in your next review.

You should also speak to someone before stopping if you are pregnant, trying to conceive, or breastfeeding, Wegovy is not recommended in pregnancy, and there is a recommended contraceptive washout period before trying to conceive. Similarly, if you are having surgery, your anaesthetic team needs to know you are taking or recently stopped a GLP-1 medicine because of its effects on gastric emptying.

If you have questions about whether stopping is the right decision at all, the broader picture on stopping semaglutide may help. For those weighing up the best approach, guidance on the most careful route off semaglutide covers practical options in more detail. The MHRA Yellow Card scheme is also open to patients who want to report any side effect they experienced while on treatment or after stopping.

If you want to talk through your options with a clinical team that takes the time to review your situation properly, start a free consultation with our prescribers, they can review your history and help you plan next steps, whether that means continuing, tapering, or transitioning to something else.